Lofexidine versus clonidine in rapid opiate detoxification - PubMed

Clinical Trial

Lofexidine versus clonidine in rapid opiate detoxification

G Gerra et al. J Subst Abuse Treat. 2001 Jul.

Abstract

The aim of the present study is to evaluate lofexidine and clonidine, in an accelerated opiate detoxification procedure (3 days), without anaesthesia. Forty heroin-dependent individuals were detoxified, evaluating withdrawal symptoms, craving levels, mood changes, urine toxicologic screens, and dropout during therapy with either (1) clonidine, oxazepam, baclofen, and ketoprofene, with naloxone and naltrexone for 3 days (20 subjects) or (2) lofexidine, oxazepam, baclofen, and ketoprofene with naloxone and naltrexone for 3 days (20 subjects). Both clonidine and lofexidine rapid detoxifications were found effective. The subjects treated with lofexidine showed significantly lower levels of withdrawal symptoms, fewer mood problems, less sedation and hypotension. No significant differences in craving levels, morphine metabolites in urine, or dropout rate were evidenced between the two groups. The early use of naltrexone during detoxification in combination with either alpha-2-agonist facilitated the acceptance for long-term naltrexone treatment. Lofexidine appeared to be more useful than clonidine in a 3-day accelerated opiate detoxification, not only to counteract withdrawal symptoms, but also in the treatment of dysphoria and mood changes. Because lofexidine does not produce hypotension, safe outpatient treatment, without hospital support, could be possible.

Similar articles

• Opioid antagonists with minimal sedation for opioid withdrawal.

  Gowing L, Ali R, White JM. Gowing L, et al. Cochrane Database Syst Rev. 2017 May 29;5(5):CD002021. doi: 10.1002/14651858.CD002021.pub4. Cochrane Database Syst Rev. 2017. PMID: 28553701 Free PMC article. Review.

• Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.

  Law FD, Diaper AM, Melichar JK, Coulton S, Nutt DJ, Myles JS. Law FD, et al. J Psychopharmacol. 2017 Aug;31(8):1046-1055. doi: 10.1177/0269881117711710. Epub 2017 Jun 20. J Psychopharmacol. 2017. PMID: 28631527 Clinical Trial.

• Rapid opiate detoxication in outpatient treatment: relationship with naltrexone compliance.

  Gerra G, Zaimovic A, Rustichelli P, Fontanesi B, Zambelli U, Timpano M, Bocchi C, Delsignore R. Gerra G, et al. J Subst Abuse Treat. 2000 Mar;18(2):185-91. doi: 10.1016/s0740-5472(99)00050-1. J Subst Abuse Treat. 2000. PMID: 10716102 Clinical Trial.

• In-patient detoxification procedures, treatment retention, and post-treatment opiate use: comparison of lofexidine + naloxone, lofexidine + placebo, and methadone.

  McCambridge J, Gossop M, Beswick T, Best D, Bearn J, Rees S, Strang J. McCambridge J, et al. Drug Alcohol Depend. 2007 Apr 17;88(1):91-5. doi: 10.1016/j.drugalcdep.2006.09.020. Epub 2006 Oct 24. Drug Alcohol Depend. 2007. PMID: 17064857 Clinical Trial.

• Lofexidine for opiate detoxification: review of recent randomised and open controlled trials.

  Strang J, Bearn J, Gossop M. Strang J, et al. Am J Addict. 1999 Fall;8(4):337-48. doi: 10.1080/105504999305749. Am J Addict. 1999. PMID: 10598217 Review.

Cited by

• Opioid antagonists with minimal sedation for opioid withdrawal.

  Gowing L, Ali R, White JM. Gowing L, et al. Cochrane Database Syst Rev. 2017 May 29;5(5):CD002021. doi: 10.1002/14651858.CD002021.pub4. Cochrane Database Syst Rev. 2017. PMID: 28553701 Free PMC article. Review.

• Alpha₂-adrenergic agonists for the management of opioid withdrawal.

  Gowing L, Farrell M, Ali R, White JM. Gowing L, et al. Cochrane Database Syst Rev. 2016 May 3;2016(5):CD002024. doi: 10.1002/14651858.CD002024.pub5. Cochrane Database Syst Rev. 2016. PMID: 27140827 Free PMC article. Review.

• Review. Evidence-based treatments of addiction.

  O'Brien CP. O'Brien CP. Philos Trans R Soc Lond B Biol Sci. 2008 Oct 12;363(1507):3277-86. doi: 10.1098/rstb.2008.0105. Philos Trans R Soc Lond B Biol Sci. 2008. PMID: 18640914 Free PMC article. Review.

• Advances in opioid antagonist treatment for opioid addiction.

  Ling W, Mooney L, Wu LT. Ling W, et al. Psychiatr Clin North Am. 2012 Jun;35(2):297-308. doi: 10.1016/j.psc.2012.03.002. Epub 2012 Apr 10. Psychiatr Clin North Am. 2012. PMID: 22640757 Free PMC article. No abstract available.

• Opioid dependence treatment: options in pharmacotherapy.

  Stotts AL, Dodrill CL, Kosten TR. Stotts AL, et al. Expert Opin Pharmacother. 2009 Aug;10(11):1727-40. doi: 10.1517/14656560903037168. Expert Opin Pharmacother. 2009. PMID: 19538000 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information